Health Care & Life Sciences » Biotechnology | BioTie Therapies Oyj

BioTie Therapies Oyj | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
274
309
359
159
307
Total Accounts Receivable
31
32
31
52
81
Inventories
26
27
36
43
38
Other Current Assets
36
41
24
19
15
Total Current Assets
367
409
451
273
442
Net Property, Plant & Equipment
17
46
40
34
37
Total Investments and Advances
93
-
-
-
1
Intangible Assets
17
616
614
1,023
717
Other Assets
5
10
8
8
2
Total Assets
607
1,081
1,116
1,342
1,198
ST Debt & Current Portion LT Debt
2
2
1
7
7
Accounts Payable
16
18
14
27
27
Other Current Liabilities
79
95
75
114
109
Total Current Liabilities
97
114
91
148
144
Long-Term Debt
4
290
297
324
364
Provision for Risks & Charges
-
53
64
72
-
Deferred Taxes
108
24
10
88
22
Other Liabilities
66
60
51
41
148
Total Liabilities
167
540
513
678
678
Common Equity (Total)
440
540
603
664
520
Total Shareholders' Equity
440
540
603
664
520
Total Equity
440
540
603
664
520
Liabilities & Shareholders' Equity
607
1,081
1,116
1,342
1,198

About BioTie Therapies Oyj

View Profile
Address
420 Saw Mill River Road
Ardsley New York 10502
United States
Employees -
Website http://www.acorda.com
Updated 09/14/2018
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury.